J
Joel E. Gallant
Researcher at Johns Hopkins University School of Medicine
Publications - 147
Citations - 18847
Joel E. Gallant is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Emtricitabine. The author has an hindex of 51, co-authored 143 publications receiving 17548 citations. Previous affiliations of Joel E. Gallant include Johns Hopkins University & University of Zurich.
Papers
More filters
Journal ArticleDOI
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
Diana Finzi,Monika Hermankova,Theodore C. Pierson,Lucy M. Carruth,Christopher B. Buck,Richard E. Chaisson,Thomas C. Quinn,Karen Chadwick,Joseph B. Margolick,Ron Brookmeyer,Joel E. Gallant,Martin Markowitz,David D. Ho,Douglas D. Richman,Robert F. Siliciano +14 more
TL;DR: In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes, and generally did not show mutations associated with resistance to the relevant antiretroviral drugs.
Journal ArticleDOI
Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel
Huldrych F. Günthard,Judith A. Aberg,Joseph J. Eron,Jennifer F Hoy,Amalio Telenti,Constance A. Benson,David M. Burger,Pedro Cahn,Joel E. Gallant,Marshall J. Glesby,Peter Reiss,Michael S. Saag,David L. Thomas,Donna M. Jacobsen,Paul A. Volberding +14 more
TL;DR: This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Journal ArticleDOI
Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Diana Finzi,Joel N. Blankson,Janet M. Siliciano,Joseph B. Margolick,Karen Chadwick,Theodore C. Pierson,Kendall A. Smith,Julianna Lisziewicz,Franco Lori,Charles Flexner,Thomas C. Quinn,Richard E. Chaisson,Eric S. Rosenberg,Bruce D. Walker,Stephen J. Gange,Joel E. Gallant,Robert F. Siliciano +16 more
TL;DR: The mean half-life of the latent reservoir was very long (43.9 months) and the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable as mentioned in this paper.
Journal ArticleDOI
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Joel E. Gallant,Schlomo Staszewski,Anton Pozniak,Edwin DeJesus,Jamal M. A. H. Suleiman,Michael D. Miller,Dion F. Coakley,Biao Lu,John J. Toole,Andrew K. Cheng +9 more
TL;DR: Through 144 weeks, the combination of tenofovir DF, lamivudine, and efavirenz was highly effective and comparable with stavudine for antiretroviral-naive patients and appeared to be associated with better lipid profiles and less lipodystrophy.
Journal ArticleDOI
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Leslie Cottle,Xinyi C. Zhang,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Sharlaa Faesen,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Sarah E. Hudelson,Andrew D. Redd,Thomas R. Fleming +35 more
TL;DR: The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners, and was associated with a 93% lower risk of linked partner infection than was delayed ART.